Before diving into today’s topic, I wanted to share a brief update. It’s hard to believe that I’m already seven months into my new practice. The clinic has grown rapidly, and I now spend the majority of my time caring for patients with melanoma, cutaneous malignancies, soft tissue and bone sarcomas, and other connective tissue tumors. One of the most rewarding aspects of this transition has been joining thee largest institution in Florida, where I’ve had the opportunity to help expand clinical trial offerings and develop new treatment programs. Much of my current work focuses on advancing innovative therapies, including cellular therapies for melanoma and emerging studies in sarcoma. After more than 15 years in oncology—as a clinician, clinical investigator, researcher, and educator—this stage of my career feels particularly meaningful. I’m fortunate to work alongside outstanding colleagues, contribute to advancing the field, and, most importantly, care for patients facing complex cancers. With that in mind, I’d like to highlight an exciting development in melanoma that has the potential to expand access to tumor-infiltrating lymphocyte (TIL) therapy for patients with BRAF-mutated disease.
Last week in clinic, I met a patient I’ll call Michael.
Michael is in his early 50s, active, working full-time, and doing everything possible to stay ahead of his metastatic melanoma. His tumor carries a BRAF mutation. Like many patients today, he received immunotherapy first and initially did well.
Then his scans showed progression.
As we discussed next steps, the conversation quickly turned to a challenge many melanoma specialists know all too well: timing.
Not timing in terms of when a treatment works.
Timing in terms of whether a patient can actually get to the treatment in the first place.
The Problem We’ve Been Facing
For patients with BRAF-mutated melanoma who progress on PD-1 therapy, there are several potential treatment options.
One important option is tumor-infiltrating lymphocyte (TIL) therapy. Today, the commercially available TIL product is Amtagvi (lifileucel), an exciting cellular therapy that uses a patient’s own immune cells to fight melanoma.
The challenge has never been whether TIL therapy is an attractive treatment option.
The challenge has been getting patients there.
Historically, the process often looked something like this:
- Progress on immunotherapy
- Evaluate for TIL therapy
- Submit for approvals
- Wait for authorization
- Schedule tumor harvest
- Coordinate tissue procurement
- Manufacture the TIL product
- Wait approximately four to five weeks for manufacturing
- Return for lymphodepleting chemotherapy, TIL infusion, and IL-2
By the time all of this happened, six to eight weeks—or sometimes longer—could pass.
In oncology, that can feel like an eternity.
What Happens During the Wait?
Many patients require treatment while waiting for TIL manufacturing.
For BRAF-mutated melanoma, that often means starting BRAF/MEK targeted therapy.
The problem is that this creates a race against the clock.
Patients are waiting for approvals.
Waiting for surgery.
Waiting for tissue collection.
Waiting for manufacturing.
Waiting for hospital scheduling.
And all the while, the disease is moving on its own timeline.
Unfortunately, some patients never make it to TIL therapy despite being excellent candidates.
That has always been one of the most frustrating parts of the process.
Enter the BRAF Pathway to TIL Program
This is why I am excited about what Iovance is developing through what I refer to as the BRAF Pathway to TIL Program.
The idea is simple but potentially transformative.
Instead of waiting until after multiple treatment decisions have already been made, eligible patients who have progressed on PD-1 therapy can be evaluated much earlier for TIL treatment.
If approved, tumor procurement can happen sooner.
The tissue can be collected sooner.
The TIL product can be manufactured sooner.
And most importantly, the product can then be stored for up to 12 months after tissue procurement.
That changes everything.
Why Earlier Tissue Procurement Matters
One of the biggest advantages of this approach is flexibility.
Once tissue has been harvested and the TIL product has been manufactured, patients and physicians suddenly have options.
A patient may decide to proceed directly to TIL therapy.
Another patient may undergo tumor procurement first and then start BRAF/MEK therapy afterward.
Some patients may achieve disease control with targeted therapy and later transition to TIL therapy at a time that makes the most clinical sense.
Instead of scrambling to coordinate tissue procurement after progression and then waiting for manufacturing, the product is already available.
The planning becomes proactive rather than reactive.
For patients, that means less uncertainty.
For providers, it means more flexibility.
The Surgical Part Is Often the Easy Part
Many people assume the difficult part of TIL therapy is obtaining tissue.
In reality, experienced centers routinely perform tumor procurement procedures.
Whether through excisional biopsy, metastasectomy, lymph node resection, or another surgical approach, tissue collection is generally very manageable.
The real challenge has always been logistics and timing.
The BRAF Pathway to TIL Program addresses exactly that problem.
Why Earlier May Be Better
Another reason this approach is appealing is that it may allow us to think about TIL therapy earlier in the treatment journey rather than waiting until patients have exhausted every available option.
There are data suggesting that outcomes may be less favorable when patients receive TIL therapy after becoming refractory to BRAF/MEK therapy compared with earlier treatment settings. While ongoing studies continue to refine the optimal sequencing strategy, these observations raise an important question:
Why wait until a patient is running out of options if we can prepare earlier?
That does not mean every patient should immediately proceed to TIL therapy.
But it does mean we should be thinking about TIL sooner.
The ability to procure tissue, manufacture the product, and have it available when needed creates opportunities that simply did not exist before.
A New Way of Thinking About Melanoma Care
What excites me most about this program is not just the treatment itself.
It’s the strategy.
For years, we have often been forced to react to progression, approvals, manufacturing timelines, and administrative hurdles.
The BRAF Pathway to TIL Program allows us to think several moves ahead.
Much like a chess player preparing for the middle game before the opening is finished, we can begin positioning patients for future treatment options before they urgently need them.
For patients with BRAF-mutated melanoma who have progressed on PD-1 therapy, that may ultimately be the greatest advantage of all.
The Bottom Line
If you have a patient with BRAF-mutated melanoma who has become refractory to PD-1 therapy, it may be time to start thinking about TIL therapy earlier than you have in the past.
The BRAF Pathway to TIL Program offers an opportunity to:
- Verify eligibility earlier
- Procure tissue earlier
- Manufacture TIL earlier
- Store the product for up to 12 months
- Preserve treatment flexibility
- Potentially help more patients successfully reach therapy
Sometimes innovation comes in the form of a new drug.
Other times, innovation comes from improving the process.
This program may do exactly that.
And for patients facing advanced melanoma, better planning can sometimes be just as important as the next treatment itself.
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.
Disclosures:
Dr. Thomas serves as a speaker for BMS, Merck, Ipsen, Natera, Immunocore, Pfizer, Sun Pharma, SpringWorks. He also receives industry grants in support of numerous clinical trials.
Disclosure: Any patient stories, scenarios, or clinical examples presented in this article are fictionalized, composite illustrations created for educational purposes. They do not describe any specific individual and are not intended to represent any actual patient treated by the author or institution.
Leave a Reply